DLI
DLI is a biological therapy with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
2
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Clinical Trials (7)
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7